SlideShare una empresa de Scribd logo
1 de 59
Descargar para leer sin conexión
COPDChronic obstructive pulmonary disease
Dr Muhammed Aslam
MBBS MD Pulmonary Medicine
www.medicalppt.blogspot.com
Outline
n INTRODUCTION
n TYPES
n PATHOLOGY
n RISK FACTORS
n CLINICAL FEATURES
n DIAGNOSIS
n MANAGEMENT
n COMPLICATION
n COPD AND ASTHMA
INTRODUCTION
n It affects more than 5 percent of the population
and is associated with high morbidity and
mortality
n It is the third-ranked cause of death in the United
States, killing more than 120,000 individuals
each year
Burden of COPD
The burden of COPD is projected to increase in coming
decades due to continued exposure to COPD risk factors and
the aging of the world’s population.
COPD is associated with significant economic burden.
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Definition of COPD
COPD, a common preventable and treatable disease, is
characterized by persistent airflow limitation that is usually
progressive and associated with an enhanced chronic
inflammatory response in the airways and the lung to noxious
particles or gases.
© Global Initiative for Chronic Obstructive Lung Disease
COPD includes
1) Chronic Bronchitis
2) Emphysema
Chronic bronchitis
Defined as a chronic productive cough
for three months in each of two
successive years in a patient in whom
other causes of chronic cough have
been excluded
Emphysema
Abnormal and permanent enlargement
of the airspaces distal to the terminal
bronchioles that is accompanied by
destruction of the airspace walls, without
obvious fibrosis
PATHOLOGY
Airways
 Chronic inflammation
 Increased numbers of goblet cells
 Mucus gland hyperplasia
 Fibrosis
 Narrowing and reduction in the number of small airways
 Airway collapse due to the loss of tethering caused by
alveolar wall destruction in emphysema
COPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
Lung Parenchyma
Emphysema affects the structures distal
to the terminal bronchiole, consisting of
the respiratory bronchiole, alveolar
ducts, alveolar sacs, and alveoli, known
collectively as the acinus.
Normal Acinus
Subtype of emphysema.
Centrilobular emphysema (Proximal acinar)
Abnormal dilation or destruction of the respiratory
bronchiole, the central portion of the acinus. It is
commonly associated with cigarette smoking,
Panacinar emphysema
Refers to enlargement or destruction of all parts of the
acinus.
Seen in alpha-1 antitrypsin deficiency and in smokers
Paraseptal emphysema
Distal acinar - the alveolar ducts are
predominantly affected.
Emphysema
Pulmonary vasculature
Intimal hyperplasia and smooth muscle hypertrophy or
hyperplasia thought to be due to chronic hypoxic
vasoconstriction of the small pulmonary arteries
Destruction of alveoli due to emphysema can lead to loss
of the associated areas of the pulmonary capillary bed
and pruning of the distal vasculature
COPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
Risk Factors for COPD
Genes
Infections
Socio-economic status
Aging Populations© 2015 Global Initiative for Chronic Obstructive Lung Disease
Genetics
Alpha 1-antitrypsin deficiency is a genetic condition that is
responsible for about 2% of cases of COPD.
In this condition, the body does not make enough of a protein,
alpha 1-antitrypsin.
Alpha 1-antitrypsin protects the lungs from damage caused by
protease enzymes, such as elastase and trypsin, that can be
released as a result of an inflammatory response to tobacco
smoke.
The characteristic symptoms of COPD are chronic and progressive
dyspnea, cough, and sputum production that can be variable from day-
to-day.
Dyspnea: Progressive, persistent and characteristically worse with
exercise.
Chronic cough: May be intermittent and may be unproductive.
Chronic sputum production: COPD patients commonly cough up sputum.
Symptoms of COPD
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Other Clinical features
 Wheezing
 Chest tightness
 Wt.loss
 Respiratory infections
Modified MRC (mMRC)Questionnaire
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Physical signs:
*Inspection:
Barrel-shaped chest ,
Accessory respiratory muscle participate ,
Prolonged expiration during quiet breathing.
Expiration through pursed lips
Paradoxical retraction of the lower interspaces during inspiration (ie,
hoover's sign)
Tripod Position
COPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
Tripod Position
Patients with end-stage
COPD may adopt
positions that relieve
dyspnea, such as leaning
forward with arms
outstretched and weight
supported on the palms
or elbows.
*Palpation:
Decreased fremitus vocalis
*Percussion :
Hyperresonant
Depressed diaphragm,
Dimination of the area of absolute cardiac dullness.
*Auscultation:
Prolonged expiration ;
Reduced breath sounds;
The presence of wheezing during quiet breathing
Crackle can be heard if infection exist.
Clinical Manifestation
SYMPTOMS
chronic cough
shortness of breath
EXPOSURE TO RISK
FACTORS
tobacco
occupation
indoor/outdoor pollution
SPIROMETRY: Required to establish diagnosis
Diagnosis of COPD
è
sputum
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Diagnosis
The presence of a post-bronchodilator FEV1/FVC < 0.70
confirms the presence of persistent airflow limitation and thus
of COPD.
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Spirometry: Normal Trace
Showing FEV1 and FVC
1 2 3 4 5 6
1
2
3
4
Volume,liters
Time, sec
FVC5
1
FEV1 = 4L
FVC = 5L
FEV1/FVC = 0.8
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Spirometry: Obstructive
Disease
Volume,liters
Time, seconds
5
4
3
2
1
1 2 3 4 5 6
FEV1 = 1.8L
FVC = 3.2L
FEV1/FVC = 0.56
Normal
Obstructive
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Classification of Severity of Airflow Limitation in
COPD*
In patients with FEV1/FVC < 0.70:
GOLD 1: Mild FEV1 > 80% predicted
GOLD 2: Moderate 50% < FEV1 < 80% predicted
GOLD 3: Severe 30% < FEV1 < 50% predicted
GOLD 4: Very Severe FEV1 < 30% predicted
*Based on Post-Bronchodilator FEV1
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Chest x-ray-Chronic bronchitis
No apparent
abnormality
Or thickened and
increased lung
markings are noted.
Chest X-Ray --emphysema
Marked over inflation is noted with flattend and low
diaphragm
Intercostal space becomes widen
A horizontal pattern of ribs
A long thin heart shadow
Decreased markings of lung peripheral vessels
COPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
CT(Computed tomography)
Greater sensitivity and specificity for emphysema
For evaluation of bullous disease
Labortory Examination
Blood examination
In excerbation or acute infection in airway,
leucocytosis may be detected.
Sputum examination
Streptococcus pneumonia
haemophilus influenzae
moraxella catarrhalis
klebsiella pneumonia
Arterial blood gas measurements (in hospital):
PaO2 < 8.0 kPa with or without PaCO2 > 6.7
kPa when breathing room air indicates
respiratory failure.
Management
Based on the principles of
Prevention of further progress of disease
Preservation and enhancement of
pulmonary functional capacity
Avoidance of exacerbations in order to
improve the quality of life.
1.Bronchodilators
Bronchodilators are central to the symptomatic
management of COPD.
Improve emptying of the lungs,reduce
dynamic hyperinflation and improve
exercise performance .
Bronchodilators
Three major classes of bronchodilators:
β2 - agonists:
Short acting: salbutamol & terbutaline
Long acting :Salmeterol & formoterol
Anticholinergic agents:
Ipratropium,tiotropium
Theophylline (a weak bronchodilator, which may
have some anti-inflammatory properties)
2.Glucocorticoids
Regular treatment with inhaled glucocorticoids is
appropriate for symptomatic patients with an
FEV1<50%pred and repeated exacerbations.
Chronic treatment with systemic glucocorticoids
should be avoided because of an unfavorable
benefit-to-risk ratio.
3. COMBINATION THERAPY
Combination therapy of long acting ß2-agonists
and inhaled corticosteroids show a significant
additional effect on pulmonary function and a
reduction in symptoms.
Mainly in patients with an FEV1<50%pred
4.Others:
Antioxidant agents
Mucolytic
In patients with severe and very severe COPD (GOLD 3 and
4) and a history of exacerbations and chronic bronchitis, the
phospodiesterase-4 inhibitor, roflumilast, reduces
exacerbations treated with oral glucocorticosteroids.
Phosphodiesterase-4 Inhibitors
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Influenza vaccines can reduce serious illness. Pneumococcal
polysaccharide vaccine is recommended for COPD patients 65
years and older and for COPD patients younger than age 65 with
an FEV1 < 40% predicted.
The use of antibiotics, other than for treating infectious
exacerbations of COPD and other bacterial infections, is currently
not indicated.
Other Pharmacologic Treatments
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Oxygen Therapy
Oxygen -- >15 h /d
Long-term oxygen therapy (LTOT) improves
survival,exercise,sleep and cognitive performance in
patients with respiratory failure.
The therapeutic goal is to maintain SaO2 ≥ 90% and
PaO2 ≥ 60mmHg at sea level and rest .
Pulmonary rehabilitation
Nutrition
Surgery:
Bullectomy
Lung volume reduction surgery
Lung transplantation
Other Treatments
Smoking cessation has the greatest capacity to
influence the natural history of COPD
Pharmacotherapy and nicotine replacement reliably
increase long-term smoking abstinence rates.
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Smoking cessation
Smoking Cessation
Nicotine replacement therapy (nicotine gum, inhaler,
nasal spray, transdermal patch, sublingual tablet, or
lozenge) as well as pharmacotherapy with varenicline,
bupropion, and nortriptyline reliably increases long-term
smoking abstinence rates and are significantly more
effective than placebo.
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Brief Strategies to Help the
Patient Willing to Quit Smoking
1. ASK - -Systematically identify all tobacco users at every
visit
2. ADVISE - Strongly urge all tobacco users to quit
3. ASSESS - Determine willingness to make a quit attempt
4. ASSIST - Aid the patient in quitting
5. ARRANGE - Schedule follow-up contact.
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Complications
Pneumothorax
Cor pulmonale
Exacerbations of copd
Respiratory failure
COPD Comorbidities
COPD patients are at increased risk for:
Cardiovascular diseases
Osteoporosis
Respiratory infections
Anxiety and Depression
Diabetes
Lung cancer
Bronchiectasis
These comorbid conditions may influence mortality and hospitalizations
and should be looked for routinely, and treated appropriately.
© 2015 Global Initiative for Chronic Obstructive Lung Disease
COPD and Asthma
COPD
l Onset in mid-life
l Symptoms slowly
progressive
l Long smoking history
ASTHMA
lOnset early in life (often childhood)
lSymptoms vary from day to day
lSymptoms worse at night/early morning
lAllergy, rhinitis, and/or eczema also present
lFamily history of asthma
© 2015 Global Initiative for Chronic Obstructive Lung Disease
Asthma-COPD overlap syndrome
"characterized by persistent airflow limitation with several
features usually associated with asthma and several
features usually associated with COPD. ACOS is
therefore identified in clinical practice by the features that
it shares with both asthma and COPD."
Tomorrow - MAY 31
World No Tobacco Day - 31 May 2016
THANK YOU !!!

Más contenido relacionado

La actualidad más candente (20)

Pneumonia
PneumoniaPneumonia
Pneumonia
 
Asthma
AsthmaAsthma
Asthma
 
Emphysema
EmphysemaEmphysema
Emphysema
 
Pleural effusion
Pleural effusionPleural effusion
Pleural effusion
 
Chronic bronchitis
Chronic bronchitisChronic bronchitis
Chronic bronchitis
 
Status asthmaticus
Status asthmaticusStatus asthmaticus
Status asthmaticus
 
Congestive cardiac failure
Congestive cardiac failureCongestive cardiac failure
Congestive cardiac failure
 
5.Bronchiectasis
5.Bronchiectasis5.Bronchiectasis
5.Bronchiectasis
 
Lung abscess
Lung abscessLung abscess
Lung abscess
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASECHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.ppt
 
Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis ppt
 
Asthma
AsthmaAsthma
Asthma
 
Pneumothorax PPT
Pneumothorax PPTPneumothorax PPT
Pneumothorax PPT
 
ARDS ppt
ARDS pptARDS ppt
ARDS ppt
 
Lungs abscess
Lungs abscessLungs abscess
Lungs abscess
 
Heart failure ppt
Heart failure pptHeart failure ppt
Heart failure ppt
 
Pulmonary Embolism
Pulmonary EmbolismPulmonary Embolism
Pulmonary Embolism
 
Congestive heart failure
Congestive heart failureCongestive heart failure
Congestive heart failure
 
bronchitis - CHRONIC BRONCHITIS
bronchitis - CHRONIC BRONCHITISbronchitis - CHRONIC BRONCHITIS
bronchitis - CHRONIC BRONCHITIS
 

Destacado

Chronic obstructive pulmonary disease (copd) power point
Chronic obstructive pulmonary disease (copd) power pointChronic obstructive pulmonary disease (copd) power point
Chronic obstructive pulmonary disease (copd) power pointwandatardy
 
Introduction to Interstitial Lung Disease(ILD) or Diffuse Parenchymal Lung ...
Introduction to Interstitial Lung Disease(ILD)  or  Diffuse Parenchymal Lung ...Introduction to Interstitial Lung Disease(ILD)  or  Diffuse Parenchymal Lung ...
Introduction to Interstitial Lung Disease(ILD) or Diffuse Parenchymal Lung ...Dr.Aslam calicut
 
Bronchial asthma and management RRT
Bronchial asthma and management  RRTBronchial asthma and management  RRT
Bronchial asthma and management RRTRanjith Thampi
 
Ventilation Perfusion Matching
Ventilation Perfusion MatchingVentilation Perfusion Matching
Ventilation Perfusion MatchingDang Thanh Tuan
 
Pleural Effusion for Undergraduates
Pleural Effusion for UndergraduatesPleural Effusion for Undergraduates
Pleural Effusion for UndergraduatesSesha Sai
 
COPD.ppt
COPD.pptCOPD.ppt
COPD.pptShama
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseimangalal
 
COPD (Chronic Obstructive Pulmonary Disease)
COPD (Chronic Obstructive Pulmonary Disease)COPD (Chronic Obstructive Pulmonary Disease)
COPD (Chronic Obstructive Pulmonary Disease)HoneymoonSwami.com
 
Bronchial asthma
Bronchial asthma Bronchial asthma
Bronchial asthma ann geo
 
Nursing management of the client with increased intracranial pressure
Nursing management of the client with increased intracranial pressureNursing management of the client with increased intracranial pressure
Nursing management of the client with increased intracranial pressureANILKUMAR BR
 
BRONCHIAL ASTHMA
BRONCHIAL ASTHMABRONCHIAL ASTHMA
BRONCHIAL ASTHMAAlinamathew
 
Digestive System Parts And Function
Digestive System Parts And FunctionDigestive System Parts And Function
Digestive System Parts And FunctionF Blanco
 
Upper respiratory disorders and nursing mangement
Upper respiratory disorders and nursing mangementUpper respiratory disorders and nursing mangement
Upper respiratory disorders and nursing mangementANILKUMAR BR
 
Dementia presentation 17 5 11
Dementia presentation 17 5 11Dementia presentation 17 5 11
Dementia presentation 17 5 11Telfordlink
 

Destacado (20)

Chronic obstructive pulmonary disease (copd) power point
Chronic obstructive pulmonary disease (copd) power pointChronic obstructive pulmonary disease (copd) power point
Chronic obstructive pulmonary disease (copd) power point
 
Introduction to Interstitial Lung Disease(ILD) or Diffuse Parenchymal Lung ...
Introduction to Interstitial Lung Disease(ILD)  or  Diffuse Parenchymal Lung ...Introduction to Interstitial Lung Disease(ILD)  or  Diffuse Parenchymal Lung ...
Introduction to Interstitial Lung Disease(ILD) or Diffuse Parenchymal Lung ...
 
Inhaler therapy
Inhaler therapyInhaler therapy
Inhaler therapy
 
Copd update 2015
Copd update 2015Copd update 2015
Copd update 2015
 
Bronchial asthma and management RRT
Bronchial asthma and management  RRTBronchial asthma and management  RRT
Bronchial asthma and management RRT
 
Ventilation Perfusion Matching
Ventilation Perfusion MatchingVentilation Perfusion Matching
Ventilation Perfusion Matching
 
Pleural Effusion for Undergraduates
Pleural Effusion for UndergraduatesPleural Effusion for Undergraduates
Pleural Effusion for Undergraduates
 
Pulmonary function testing
Pulmonary function testingPulmonary function testing
Pulmonary function testing
 
COPD.ppt
COPD.pptCOPD.ppt
COPD.ppt
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
 
COPD (Chronic Obstructive Pulmonary Disease)
COPD (Chronic Obstructive Pulmonary Disease)COPD (Chronic Obstructive Pulmonary Disease)
COPD (Chronic Obstructive Pulmonary Disease)
 
Asthma versus COPD
Asthma versus COPDAsthma versus COPD
Asthma versus COPD
 
Bronchial asthma
Bronchial asthma Bronchial asthma
Bronchial asthma
 
Nursing management of the client with increased intracranial pressure
Nursing management of the client with increased intracranial pressureNursing management of the client with increased intracranial pressure
Nursing management of the client with increased intracranial pressure
 
Copd imp د. جيهان
Copd imp د. جيهانCopd imp د. جيهان
Copd imp د. جيهان
 
Bronchiectasis
BronchiectasisBronchiectasis
Bronchiectasis
 
BRONCHIAL ASTHMA
BRONCHIAL ASTHMABRONCHIAL ASTHMA
BRONCHIAL ASTHMA
 
Digestive System Parts And Function
Digestive System Parts And FunctionDigestive System Parts And Function
Digestive System Parts And Function
 
Upper respiratory disorders and nursing mangement
Upper respiratory disorders and nursing mangementUpper respiratory disorders and nursing mangement
Upper respiratory disorders and nursing mangement
 
Dementia presentation 17 5 11
Dementia presentation 17 5 11Dementia presentation 17 5 11
Dementia presentation 17 5 11
 

Similar a COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam

Copd lecture notes
Copd lecture notesCopd lecture notes
Copd lecture noteshomebwoi
 
COPD(Chronic Obstructive Pulmonary Disease)Ayurveda
COPD(Chronic Obstructive Pulmonary Disease)AyurvedaCOPD(Chronic Obstructive Pulmonary Disease)Ayurveda
COPD(Chronic Obstructive Pulmonary Disease)AyurvedaRaghavendraPujari1
 
Ckd chief (2)
Ckd chief (2)Ckd chief (2)
Ckd chief (2)Rajiv Lal
 
Copd seminar
Copd seminarCopd seminar
Copd seminarhemin sab
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseDrRavi Jain
 
Chronic obstructive pulmonary disease (COPD)- Preeti sharma
Chronic obstructive pulmonary disease (COPD)- Preeti sharmaChronic obstructive pulmonary disease (COPD)- Preeti sharma
Chronic obstructive pulmonary disease (COPD)- Preeti sharmaEducate with smile
 
copdppt-210122180445 (1).pdf
copdppt-210122180445 (1).pdfcopdppt-210122180445 (1).pdf
copdppt-210122180445 (1).pdfShikharSingh98
 
Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Rahil Dalal
 
Chronic obstructive pulmonary disease by aminu arzet
Chronic obstructive pulmonary disease by aminu arzetChronic obstructive pulmonary disease by aminu arzet
Chronic obstructive pulmonary disease by aminu arzetAminuArzet
 
chronic obstructive pulmoary disease
chronic obstructive pulmoary diseasechronic obstructive pulmoary disease
chronic obstructive pulmoary diseaseRaghunandan Singh
 
copdppt-210122180445.docx
copdppt-210122180445.docxcopdppt-210122180445.docx
copdppt-210122180445.docxShikharSingh98
 

Similar a COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam (20)

COPD & asthma.ppt
COPD & asthma.pptCOPD & asthma.ppt
COPD & asthma.ppt
 
Copd lecture notes
Copd lecture notesCopd lecture notes
Copd lecture notes
 
COPD(Chronic Obstructive Pulmonary Disease)Ayurveda
COPD(Chronic Obstructive Pulmonary Disease)AyurvedaCOPD(Chronic Obstructive Pulmonary Disease)Ayurveda
COPD(Chronic Obstructive Pulmonary Disease)Ayurveda
 
Copd
CopdCopd
Copd
 
Ckd chief (2)
Ckd chief (2)Ckd chief (2)
Ckd chief (2)
 
Copd seminar
Copd seminarCopd seminar
Copd seminar
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
 
2 COPD.ppt
2  COPD.ppt2  COPD.ppt
2 COPD.ppt
 
COPD.pptx
COPD.pptxCOPD.pptx
COPD.pptx
 
COPD
COPD COPD
COPD
 
Chronic obstructive pulmonary disease (COPD)- Preeti sharma
Chronic obstructive pulmonary disease (COPD)- Preeti sharmaChronic obstructive pulmonary disease (COPD)- Preeti sharma
Chronic obstructive pulmonary disease (COPD)- Preeti sharma
 
copdppt-210122180445 (1).pdf
copdppt-210122180445 (1).pdfcopdppt-210122180445 (1).pdf
copdppt-210122180445 (1).pdf
 
Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)
 
Chronic obstructive pulmonary disease by aminu arzet
Chronic obstructive pulmonary disease by aminu arzetChronic obstructive pulmonary disease by aminu arzet
Chronic obstructive pulmonary disease by aminu arzet
 
chronic obstructive pulmoary disease
chronic obstructive pulmoary diseasechronic obstructive pulmoary disease
chronic obstructive pulmoary disease
 
copdppt-210122180445.docx
copdppt-210122180445.docxcopdppt-210122180445.docx
copdppt-210122180445.docx
 
01.copd
01.copd01.copd
01.copd
 
COPD -MA.pptx
COPD -MA.pptxCOPD -MA.pptx
COPD -MA.pptx
 
COPD-Report.pdf
COPD-Report.pdfCOPD-Report.pdf
COPD-Report.pdf
 
Copd 2012 pdf
Copd 2012 pdf Copd 2012 pdf
Copd 2012 pdf
 

Más de Dr.Aslam calicut

Novel coronavirus 2019 china nCoV2019
Novel coronavirus 2019 china nCoV2019Novel coronavirus 2019 china nCoV2019
Novel coronavirus 2019 china nCoV2019Dr.Aslam calicut
 
E cigarettes vaping and vaping induced lung injury EVALI
E cigarettes vaping and vaping induced lung injury EVALIE cigarettes vaping and vaping induced lung injury EVALI
E cigarettes vaping and vaping induced lung injury EVALIDr.Aslam calicut
 
Bacterial flora in sputum and antibiotic sensitivity in exacerbations of bron...
Bacterial flora in sputum and antibiotic sensitivity in exacerbations of bron...Bacterial flora in sputum and antibiotic sensitivity in exacerbations of bron...
Bacterial flora in sputum and antibiotic sensitivity in exacerbations of bron...Dr.Aslam calicut
 
Obstructive Sleep Apnoea and the Metabolic Syndrome
Obstructive Sleep Apnoea and the  Metabolic SyndromeObstructive Sleep Apnoea and the  Metabolic Syndrome
Obstructive Sleep Apnoea and the Metabolic SyndromeDr.Aslam calicut
 
Napcon 2014 presentation abstract
Napcon 2014 presentation abstractNapcon 2014 presentation abstract
Napcon 2014 presentation abstractDr.Aslam calicut
 
Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA)Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA)Dr.Aslam calicut
 
Changes in Respiratory System in Pregnancy
Changes in Respiratory  System in PregnancyChanges in Respiratory  System in Pregnancy
Changes in Respiratory System in PregnancyDr.Aslam calicut
 
High-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPDHigh-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPDDr.Aslam calicut
 

Más de Dr.Aslam calicut (13)

Novel coronavirus 2019 china nCoV2019
Novel coronavirus 2019 china nCoV2019Novel coronavirus 2019 china nCoV2019
Novel coronavirus 2019 china nCoV2019
 
E cigarettes vaping and vaping induced lung injury EVALI
E cigarettes vaping and vaping induced lung injury EVALIE cigarettes vaping and vaping induced lung injury EVALI
E cigarettes vaping and vaping induced lung injury EVALI
 
Bacterial flora in sputum and antibiotic sensitivity in exacerbations of bron...
Bacterial flora in sputum and antibiotic sensitivity in exacerbations of bron...Bacterial flora in sputum and antibiotic sensitivity in exacerbations of bron...
Bacterial flora in sputum and antibiotic sensitivity in exacerbations of bron...
 
Obstructive Sleep Apnoea and the Metabolic Syndrome
Obstructive Sleep Apnoea and the  Metabolic SyndromeObstructive Sleep Apnoea and the  Metabolic Syndrome
Obstructive Sleep Apnoea and the Metabolic Syndrome
 
Napcon 2014 presentation abstract
Napcon 2014 presentation abstractNapcon 2014 presentation abstract
Napcon 2014 presentation abstract
 
Polysomnography
PolysomnographyPolysomnography
Polysomnography
 
Diastolic murmurs
Diastolic murmursDiastolic murmurs
Diastolic murmurs
 
Systolic murmurs
Systolic murmursSystolic murmurs
Systolic murmurs
 
Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA)Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA)
 
PARA PNEUMONIC EFFUSION
PARA PNEUMONIC EFFUSIONPARA PNEUMONIC EFFUSION
PARA PNEUMONIC EFFUSION
 
Changes in Respiratory System in Pregnancy
Changes in Respiratory  System in PregnancyChanges in Respiratory  System in Pregnancy
Changes in Respiratory System in Pregnancy
 
Ards new
Ards newArds new
Ards new
 
High-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPDHigh-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPD
 

Último

Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 

Último (20)

Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 

COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam

  • 1. COPDChronic obstructive pulmonary disease Dr Muhammed Aslam MBBS MD Pulmonary Medicine www.medicalppt.blogspot.com
  • 2. Outline n INTRODUCTION n TYPES n PATHOLOGY n RISK FACTORS n CLINICAL FEATURES n DIAGNOSIS n MANAGEMENT n COMPLICATION n COPD AND ASTHMA
  • 3. INTRODUCTION n It affects more than 5 percent of the population and is associated with high morbidity and mortality n It is the third-ranked cause of death in the United States, killing more than 120,000 individuals each year
  • 4. Burden of COPD The burden of COPD is projected to increase in coming decades due to continued exposure to COPD risk factors and the aging of the world’s population. COPD is associated with significant economic burden. © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 5. Definition of COPD COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. © Global Initiative for Chronic Obstructive Lung Disease
  • 6. COPD includes 1) Chronic Bronchitis 2) Emphysema
  • 7. Chronic bronchitis Defined as a chronic productive cough for three months in each of two successive years in a patient in whom other causes of chronic cough have been excluded
  • 8. Emphysema Abnormal and permanent enlargement of the airspaces distal to the terminal bronchioles that is accompanied by destruction of the airspace walls, without obvious fibrosis
  • 10. Airways  Chronic inflammation  Increased numbers of goblet cells  Mucus gland hyperplasia  Fibrosis  Narrowing and reduction in the number of small airways  Airway collapse due to the loss of tethering caused by alveolar wall destruction in emphysema
  • 12. Lung Parenchyma Emphysema affects the structures distal to the terminal bronchiole, consisting of the respiratory bronchiole, alveolar ducts, alveolar sacs, and alveoli, known collectively as the acinus.
  • 14. Subtype of emphysema. Centrilobular emphysema (Proximal acinar) Abnormal dilation or destruction of the respiratory bronchiole, the central portion of the acinus. It is commonly associated with cigarette smoking,
  • 15. Panacinar emphysema Refers to enlargement or destruction of all parts of the acinus. Seen in alpha-1 antitrypsin deficiency and in smokers
  • 16. Paraseptal emphysema Distal acinar - the alveolar ducts are predominantly affected.
  • 18. Pulmonary vasculature Intimal hyperplasia and smooth muscle hypertrophy or hyperplasia thought to be due to chronic hypoxic vasoconstriction of the small pulmonary arteries Destruction of alveoli due to emphysema can lead to loss of the associated areas of the pulmonary capillary bed and pruning of the distal vasculature
  • 20. Risk Factors for COPD Genes Infections Socio-economic status Aging Populations© 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 21. Genetics Alpha 1-antitrypsin deficiency is a genetic condition that is responsible for about 2% of cases of COPD. In this condition, the body does not make enough of a protein, alpha 1-antitrypsin. Alpha 1-antitrypsin protects the lungs from damage caused by protease enzymes, such as elastase and trypsin, that can be released as a result of an inflammatory response to tobacco smoke.
  • 22. The characteristic symptoms of COPD are chronic and progressive dyspnea, cough, and sputum production that can be variable from day- to-day. Dyspnea: Progressive, persistent and characteristically worse with exercise. Chronic cough: May be intermittent and may be unproductive. Chronic sputum production: COPD patients commonly cough up sputum. Symptoms of COPD © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 23. Other Clinical features  Wheezing  Chest tightness  Wt.loss  Respiratory infections
  • 24. Modified MRC (mMRC)Questionnaire © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 25. Physical signs: *Inspection: Barrel-shaped chest , Accessory respiratory muscle participate , Prolonged expiration during quiet breathing. Expiration through pursed lips Paradoxical retraction of the lower interspaces during inspiration (ie, hoover's sign) Tripod Position
  • 27. Tripod Position Patients with end-stage COPD may adopt positions that relieve dyspnea, such as leaning forward with arms outstretched and weight supported on the palms or elbows.
  • 28. *Palpation: Decreased fremitus vocalis *Percussion : Hyperresonant Depressed diaphragm, Dimination of the area of absolute cardiac dullness. *Auscultation: Prolonged expiration ; Reduced breath sounds; The presence of wheezing during quiet breathing Crackle can be heard if infection exist. Clinical Manifestation
  • 29. SYMPTOMS chronic cough shortness of breath EXPOSURE TO RISK FACTORS tobacco occupation indoor/outdoor pollution SPIROMETRY: Required to establish diagnosis Diagnosis of COPD è sputum © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 30. Diagnosis The presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD. © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 31. Spirometry: Normal Trace Showing FEV1 and FVC 1 2 3 4 5 6 1 2 3 4 Volume,liters Time, sec FVC5 1 FEV1 = 4L FVC = 5L FEV1/FVC = 0.8 © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 32. Spirometry: Obstructive Disease Volume,liters Time, seconds 5 4 3 2 1 1 2 3 4 5 6 FEV1 = 1.8L FVC = 3.2L FEV1/FVC = 0.56 Normal Obstructive © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 33. Classification of Severity of Airflow Limitation in COPD* In patients with FEV1/FVC < 0.70: GOLD 1: Mild FEV1 > 80% predicted GOLD 2: Moderate 50% < FEV1 < 80% predicted GOLD 3: Severe 30% < FEV1 < 50% predicted GOLD 4: Very Severe FEV1 < 30% predicted *Based on Post-Bronchodilator FEV1 © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 34. Chest x-ray-Chronic bronchitis No apparent abnormality Or thickened and increased lung markings are noted.
  • 35. Chest X-Ray --emphysema Marked over inflation is noted with flattend and low diaphragm Intercostal space becomes widen A horizontal pattern of ribs A long thin heart shadow Decreased markings of lung peripheral vessels
  • 37. CT(Computed tomography) Greater sensitivity and specificity for emphysema For evaluation of bullous disease
  • 38. Labortory Examination Blood examination In excerbation or acute infection in airway, leucocytosis may be detected. Sputum examination Streptococcus pneumonia haemophilus influenzae moraxella catarrhalis klebsiella pneumonia
  • 39. Arterial blood gas measurements (in hospital): PaO2 < 8.0 kPa with or without PaCO2 > 6.7 kPa when breathing room air indicates respiratory failure.
  • 40. Management Based on the principles of Prevention of further progress of disease Preservation and enhancement of pulmonary functional capacity Avoidance of exacerbations in order to improve the quality of life.
  • 41. 1.Bronchodilators Bronchodilators are central to the symptomatic management of COPD. Improve emptying of the lungs,reduce dynamic hyperinflation and improve exercise performance .
  • 42. Bronchodilators Three major classes of bronchodilators: β2 - agonists: Short acting: salbutamol & terbutaline Long acting :Salmeterol & formoterol Anticholinergic agents: Ipratropium,tiotropium Theophylline (a weak bronchodilator, which may have some anti-inflammatory properties)
  • 43. 2.Glucocorticoids Regular treatment with inhaled glucocorticoids is appropriate for symptomatic patients with an FEV1<50%pred and repeated exacerbations. Chronic treatment with systemic glucocorticoids should be avoided because of an unfavorable benefit-to-risk ratio.
  • 44. 3. COMBINATION THERAPY Combination therapy of long acting ß2-agonists and inhaled corticosteroids show a significant additional effect on pulmonary function and a reduction in symptoms. Mainly in patients with an FEV1<50%pred
  • 46. In patients with severe and very severe COPD (GOLD 3 and 4) and a history of exacerbations and chronic bronchitis, the phospodiesterase-4 inhibitor, roflumilast, reduces exacerbations treated with oral glucocorticosteroids. Phosphodiesterase-4 Inhibitors © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 47. Influenza vaccines can reduce serious illness. Pneumococcal polysaccharide vaccine is recommended for COPD patients 65 years and older and for COPD patients younger than age 65 with an FEV1 < 40% predicted. The use of antibiotics, other than for treating infectious exacerbations of COPD and other bacterial infections, is currently not indicated. Other Pharmacologic Treatments © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 48. Oxygen Therapy Oxygen -- >15 h /d Long-term oxygen therapy (LTOT) improves survival,exercise,sleep and cognitive performance in patients with respiratory failure. The therapeutic goal is to maintain SaO2 ≥ 90% and PaO2 ≥ 60mmHg at sea level and rest .
  • 49. Pulmonary rehabilitation Nutrition Surgery: Bullectomy Lung volume reduction surgery Lung transplantation Other Treatments
  • 50. Smoking cessation has the greatest capacity to influence the natural history of COPD Pharmacotherapy and nicotine replacement reliably increase long-term smoking abstinence rates. © 2015 Global Initiative for Chronic Obstructive Lung Disease Smoking cessation
  • 51. Smoking Cessation Nicotine replacement therapy (nicotine gum, inhaler, nasal spray, transdermal patch, sublingual tablet, or lozenge) as well as pharmacotherapy with varenicline, bupropion, and nortriptyline reliably increases long-term smoking abstinence rates and are significantly more effective than placebo. © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 52. Brief Strategies to Help the Patient Willing to Quit Smoking 1. ASK - -Systematically identify all tobacco users at every visit 2. ADVISE - Strongly urge all tobacco users to quit 3. ASSESS - Determine willingness to make a quit attempt 4. ASSIST - Aid the patient in quitting 5. ARRANGE - Schedule follow-up contact. © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 54. COPD Comorbidities COPD patients are at increased risk for: Cardiovascular diseases Osteoporosis Respiratory infections Anxiety and Depression Diabetes Lung cancer Bronchiectasis These comorbid conditions may influence mortality and hospitalizations and should be looked for routinely, and treated appropriately. © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 55. COPD and Asthma COPD l Onset in mid-life l Symptoms slowly progressive l Long smoking history ASTHMA lOnset early in life (often childhood) lSymptoms vary from day to day lSymptoms worse at night/early morning lAllergy, rhinitis, and/or eczema also present lFamily history of asthma © 2015 Global Initiative for Chronic Obstructive Lung Disease
  • 56. Asthma-COPD overlap syndrome "characterized by persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD. ACOS is therefore identified in clinical practice by the features that it shares with both asthma and COPD."
  • 58. World No Tobacco Day - 31 May 2016